Specific Inhibition of Caspase-3 by a Competitive DARPin: Molecular Mimicry between Native and Designed Inhibitors  by Schroeder, Thilo et al.
Structure
ArticleSpecific Inhibition of Caspase-3
by a Competitive DARPin: Molecular Mimicry
between Native and Designed Inhibitors
Thilo Schroeder,1,2 JonasBarandun,1,2,3 Andreas Flu¨tsch,1,2 ChristopheBriand,1 Peer R.E.Mittl,1 andMarkusG. Gru¨tter1,*
1Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zu¨rich, Switzerland
2These authors contributed equally to this work
3Present address: Institute of Molecular Biology and Biophysics, Schafmattstrasse 20, ETH Zu¨rich, CH-8093 Zu¨rich, Switzerland
*Correspondence: gruetter@bioc.uzh.ch
http://dx.doi.org/10.1016/j.str.2012.12.011SUMMARY
Dysregulation of apoptosis is associatedwith several
human diseases. The main apoptotic mediators are
caspases, which propagate death signals to down-
stream targets. Executioner caspase-3 is respon-
sible for the majority of cleavage events and its
therapeutic potential is of high interest with to date
several available active site peptide inhibitors. These
molecules inhibit caspase-3, but also homologous
caspases. Here, we describe caspase-3 specific
inhibitors D3.4 and D3.8, which have been selected
from a library of designed ankyrin repeat proteins
(DARPins). The crystal structures of D3.4 and
mutants thereof show how high specificity and inhi-
bition is achieved. They also show similarities in the
binding mode with that of the natural caspase inhib-
itor XIAP (X-linked inhibitor of apoptosis). The kinetic
data reveal a competitive inhibition mechanism. D3.4
is specific for caspase-3 and does not bind the highly
homologous caspase-7. D3.4 therefore is an excel-
lent tool to define the precise role of caspase-3 in
the various apoptotic pathways.
INTRODUCTION
Apoptosis is a central process for the development and tissue
homeostasis of multicellular organisms. It is characterized
by morphological changes such as nuclear fragmentation,
membrane blebbing, or the formation of apoptotic bodies (Wyllie
et al., 1980). In multicellular organisms including humans,
improper regulation of apoptosis leads to a variety of pathologies
such as cancer, autoimmune diseases, and neurodegenerative
disorders (Riedl and Shi, 2004). Apoptosis is triggered by various
internal and external stimuli, which are propagated by different
pathways. Common to all apoptotic pathways are caspases
(Fuentes-Prior and Salvesen, 2004; Gru¨tter, 2000; Riedl and
Shi, 2004). These proteins are synthesized as inactive pro-
enzymes and activated upon triggering of the cell death
machinery: The activation of initiator caspases occurs through
dimerization (induced proximity model; Boatright et al., 2003;Structure 21, 27Muzio et al., 1998), followed by autoproteolytic cleavage of the
prodomain and the linker between the two subdomains. Execu-
tioner caspases exist as dimeric zymogens and are activated by
proteolytic cleavage of the N-terminal pro-peptide and the
intersubunit linker (Fuentes-Prior and Salvesen, 2004). Active
caspases are dimers of two catalytic domains with a small p10
and a large p20 chain.
Of the 11 known human caspases, caspase-3 plays a promi-
nent role in the apoptotic cascade. Caspase-3 is activated by
intrinsic and/or extrinsic death signals and it executes cell death
by the cleavage of downstream key mediators of apoptosis
(Timmer and Salvesen, 2007). Because apoptosis is a dangerous
process for the cell, caspase activation is strictly controlled and
all apoptotic signaling pathways are tightly regulated. All
caspases recognize tetrapeptide sequences, which are charac-
terized by an aspartic acid at the C terminus (P1 position) and
either tryptophan, aspartic acid or leucine residues at the
N terminus (P4 position) conferring selectivity for caspase-1, -3,
and -8, respectively. The P4 selectivity has been attributed to
different interactions with residues in loops flanking the P4
binding pocket (Mittl et al., 1997; Rotonda et al., 1996). However,
the selectivity of short peptidic substrates remains controversial.
It has been reported that the in vitro selectivity of caspase-3 for
a substrate harboring a P4 aspartic acid is at least 100-fold
higher than that for a glutamate or an asparagine (Stennicke
et al., 2000). Despite this finding, commercially available peptide
substrates failed to exhibit the expected caspase selectivity
(McStay et al., 2008). Caspase-3 is the most unrestrained and
efficient caspase and it is often more active in cleaving short
peptide substrates than the caspase for which the peptide
substrate was designed for (McStay et al., 2008). This analysis
raised doubt regarding the use of short peptides to dissect
signaling cascades leading to apoptosis. The observation that
naturally occurring caspase inhibitors, such as X-linked inhibitor
of apoptosis (XIAP), are highly specific for caspase-3 and -7
(Deveraux et al., 1997; Roy et al., 1997) suggests that specificity
can be gained by extending the size of the inhibitor. Caspases
are attractive drug targets because they are implicated in various
diseases. Therefore, selective and potent caspase-specific
inhibitors are highly desirable.
To develop a caspase-3 specific inhibitor, we used the
Designed Ankyrin Repeat Protein (DARPin) technology (Binz
et al., 2003). From a highly diverse library of DARPin molecules,
binders that recognize the target molecule can be selected by7–289, February 5, 2013 ª2013 Elsevier Ltd All rights reserved 277
Figure 1. Sequence Alignment of Caspase-3-Specific DARPin Binders
The general DARPin sequence is shown with the consensus sequence in black and the randomized amino acid positions in red (X, any of the 20 natural amino
acids except cysteine, glycine, or proline; Z, any of the amino acids asparagine, histidine, or tyrosine). Four DARPin sequences are aligned to the consensus
sequence with identical residues represented as a dot. Amino acids involved in the interaction with caspase-3 are colored in orange. Differences among the D3.4
and D3.8 sequences are highlighted in green. The D3.4_S76Rmutation is marked by a red box. The sequence number is based on D3.4, a N2C DARPin that lacks
the first internal repeat.
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Caspase-3 Directed DARPinseither ribosome- or phage display (Steiner et al., 2006; Zahnd
et al., 2007). DARPins consist of N- and C-terminal capping
repeats and two or three internal repeats. These internal repeats
recognize the target molecule by means of specific amino acids
that are randomized in the DARPin library. DARPins possess
several beneficial properties that make them attractive for bio-
technological applications. They are thermodynamically stable,
easily produced, and do not contain cysteine residues allowing
intracellular applications (Binz et al., 2005). Highly selective
DARPins have been successfully selected and described for
a variety of different target proteins such as caspase-2 (Schwe-
izer et al., 2007) or kinase inhibitors (Amstutz et al., 2005), crys-
tallization chaperones (Sennhauser et al., 2007), HIV inhibitors
(Schweizer et al., 2008), and tumor-targeting binding molecules
(Zahnd et al., 2010).
Here, we report the selection and characterization of
DARPins that bind to active caspase-3. Kinetic and binding
experiments revealed that DARPins D3.4 and D3.8 are compet-
itive caspase-3 inhibitors that do not recognize other members
of the caspase family at all (D3.4) or only extremely weakly
caspase-7 (D3.8). The structure of the caspase-3/D3.4 complex
reveals the critical interactions leading to high specificity and
tight binding and analogies to XIAP inhibition.
RESULTS
Selection of Caspase-3-Specific DARPin Binders
A DNA library containing NI2C and NI3C DARPins was used
to select caspase-3 binders by ribosome display (Zahnd
et al., 2007). After four selection rounds, 768 putative binders
were screened by crude cell extract ELISA yielding 29 clones
that possessed submicromolar affinities for caspase-3. These
high affinity binders were individually expressed, purified, and
their binding affinities for caspase-3 were determined by surface
plasmon resonance (SPR) analysis. Four of the selected
DARPins showed affinities below 10 nM (Figure S1 available278 Structure 21, 277–289, February 5, 2013 ª2013 Elsevier Ltd All ronline). Their sequences were aligned and are shown in Figure 1.
Although DARPins D3.4 and D3.8 contain 2 and 3 internal
repeats, respectively, they possess the highest sequence simi-
larity. Of the 14 randomized positions of the internal repeats
seven residues are identical. When comparing the sequences
of DARPin D3.6 and D3.13 only four residues in a total of 21
randomized positions are identical. Despite the different
numbers of internal repeats all four DARPins possess very
high affinities for caspase-3. SPR analysis revealed that
D3.4, D3.6, D3.8 and D3.13 bind caspase-3 with KD values of
9.6 ± 1.1 nM, 8.8 ± 2.0 nM, 3.4 ± 0.4 nM, and 7.7 ± 0.4 nM,
respectively (Table 1). These KD values were determined based
on equilibrium analyses of the SPR signal. We used the hetero-
geneous ligand model to determine the kinetic values (Table 1),
which suggests two epitopes with substantially different binding
affinities (Morton et al., 1995).
Inhibition of Caspase-3 by DARPins D3.4 and D3.8
The inhibitory properties of the purified DARPins were analyzed
using two different approaches. Initially the ability of the
DARPins to inhibit the hydrolysis of the short chromogenic
caspase-3 substrate Ac-DEVD-AMC was measured. These
initial tests revealed that D3.4 and D3.8 inhibit the hydrolysis
of the standard caspase-3 substrate with Ki values of 16.8 ±
0.3 nM and 6.7 ± 0.2 nM, respectively, whereas D3.6 and
D3.13 showed no detectable inhibitory activities (Table 1). To
characterize the mode of inhibition (competitive versus uncom-
petitive), specific velocity plot (Figure S2; Baici, 1981) analysis
was performed, which yields the ratio between competitive
and uncompetitive inhibitor constants (a) and the turnover
rate of free enzyme to inhibited enzyme (b). For both DARPins
we determined equal values of a =N and b = 0, demonstrating
that D3.4 and D3.8 are purely competitive inhibitors of caspase-
3 (Table 1).
In the past, short peptide substrates have been extensively
used for the characterization of proteases, because theights reserved
Table 1. Kinetic Constants and Characteristics of the Interaction
DARPin
Kinetic
kon1(M
1s1) koff1(s
1) KD1(M) kon2(M
1s1) koff2(s
1) KD2(M)
D3.4 2.85 3 105 8.81 3 103 3.09 3 108 1.12 3 106 1.13 3 103 1.01 3 109
D3.4_S76R 1.74 3 105 4.20 3 103 2.42 3 108 1.62 3 106 7.45 3 104 4.61 3 1010
D3.6 1.48 3 105 1.13 3 103 7.63 3 109 1.46 3 106 1.00 3 102 6.88 3 109
D3.8 1.77 3 105 2.49 3 103 1.41 3 108 2.44 3 106 1.11 3 104 4.57 3 1011
D3.13 2.74 3 105 1.24 3 103 4.51 3 109 2.31 3 106 7.86 3 103 3.41 3 109
DARPin
Equlibrium Inhibition Interaction
KD(nM) KI(nM) a b SC A˚
2 DiG kcal/mol
D3.4 9.6 ± 1.1 16.8 N 0 0.740 875.95 6.1
D3.4_S76R 6.0 ± 0.5 3.5 N 0 0.725 907.55 7.1
D3.6 8.8 ± 2.0 – – – – – –
D3.8 3.4 ± 0.4 6.7 N 0 nd nd nd
D3.13 7.7 ± 0.4 – – – – – –
See also Figures S1 and S2. nd, not determined.
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Caspase-3 Directed DARPinsdetermination of rate constants is straightforward in those exper-
iments. On the other hand, short peptide substrates represent
a rather artificial situation because these substrates utilize
a very limited number of binding interactions. Natural protease
substrates are significantly larger and consequently their binding
is guided by a broader set of interactions. Therefore, we tested
whether the selected DARPins also inhibit the processing of
PARP-1, one of the best-characterized caspase-3 substrates.
The 116-kDa PARP-1 is specifically cleaved by caspases-3
and -7 on the C-terminal side of Asp216 into an 85-kDa and
a 31-kDa fragment (Lazebnik et al., 1994). The addition of 10-
fold molar excess of D3.4 or D3.8 over caspase-3 inhibited the
cleavage of PARP-1 by 90%, whereas the addition of E3_5,
a DARPin that does not bind caspase-3, showed no effect on
the cleavage of PARP-1 (Figure 2). In addition, a 50-fold molar
excess of the caspase-3 DARPin inhibitors completely abolishes
PARP-1 cleavage (Figure 2).
Specificity of DARPins D3.4 and D3.8
All commercially available caspase inhibitors are capable of
inhibiting both caspases-3 and -7 equally well (McStay et al.,
2008). We investigated the caspase selectivity of D3.4 and
D3.8 by measuring the binding affinity and inhibitory activity
against caspase-7 (56% sequence identity with caspase-3)
and the more distantly related caspase-6 (41% sequence iden-
tity). SPR analysis did not show any detectable binding of the
caspase-3 directed DARPins D3.4 and D3.8 to caspases-6
or -7 (Figure S3), suggesting that both DARPins are highly
specific for caspase-3. These results are consistent with
the activity measurements where D3.4 and D3.8 were also
unable to inhibit PARP-1 cleavage by caspase-7 (Figure 2).
Probing the ability of D3.4 and D3.8 to inhibit the hydrolysis of
chromogenic tetrapeptide substrates by caspases-1, -2, -4, -5,
-6, -7, -8, and -9 revealed that D3.4 is highly specific for cas-
pase-3 and cannot inhibit any other tested caspase, whereas
D3.8 has a moderate inhibitory activity against caspase-7
(Figures 3 and S4). A 1,000-fold excess of D3.8 decreases the
activity of caspase-7 to approximately 40%.Structure 21, 27Crystal Structure Analysis of the Caspase-3/DARPin
D3.4 Complex
To understand the structural basis for the inhibition mechanism
of caspase-3 by DARPins the crystal structure of the caspase-
3/D3.4 complex was determined at 2.1 A˚ resolution. The details
of the structure determination (data collection and refinement)
are listed in Table 2. In the crystal structure the asymmetric
unit contains one (p12, p17)2 caspase-3 heterotetramer and
two D3.4 molecules (Figure 4A). In the complex every DARPin
buries a surface area of 876 A˚2. A surface complementarity index
of 0.74 indicates a good fit between D3.4 and caspase-3
(Table 1). The interface involves residues from the N-terminal
capping repeat and the two internal repeats of the DARPin,
which form specific hydrogen bonds and hydrophobic interac-
tions with the caspase (Figure 4A). The crystal structure reveals
first of all that D3.4 binds in the active site pocket of caspase-3
and prevents substrate molecules from accessing the catalytic
residues (Figure 4A). The b-turns of D3.4 point toward the
b strand of caspase-3 that is responsible for the recognition of
the substrate by main chain hydrogen bonds (residues 205 to
207). This observation agrees very well with the kinetic analysis
of the inhibition mechanism, where no uncompetitive contribu-
tion was observed (a = N). Therefore, structural and kinetic
analyses consistently classify D3.4 as a purely competitive
caspase-3 inhibitor (Figure S2).
When comparing the caspase-3/D3.4 complex with previously
published caspase/protein complexes, such as the caspase-2/
AR_F8 (Schweizer et al., 2007) or the natural caspase-3/XIAP
complexes (Riedl et al., 2001), the following features can be high-
lighted: (1) DARPins AR_F8 and D3.4 both bind to loop-4 (also
termed 381-loop). However, AR_F8 binds from the backside
and inhibits caspase-2 by an allosteric mechanism (Figure 4B).
(2) D3.4 and XIAP are competitive caspase-3 inhibitors, but the
main chains of D3.4 and the N-terminal extension loop of XIAP
run in opposite directions (Figure 4C).
The binding mode of D3.4 shows similarities to the binding of
natural substrates (based on inhibitor structures) and the natural
inhibitor XIAP. Asp45 of D3.4 is located in the b-turn that7–289, February 5, 2013 ª2013 Elsevier Ltd All rights reserved 279
Figure 2. Inhibition of Caspase-3-Dependent PARP-1 Cleavage by
DARPin Inhibitors
The cleavage of PARP-1 by caspase-3 (40 nM) and -7 (150 nM) was analyzed
by SDS-PAGE (upper panel). Full length and cleaved PARP-1 (cPARP-1) were
detected by a specific antibody that recognizes both forms. None of the
selected DARPins cleave PARP-1 themselves. DARPins were added at 10-,
50-, and 100-fold molar excess per active site (lower panel).
Figure 3. Specificity and Inhibition of Selected DARPins for
Caspase-3, -6, and -7
(A–C) The relative enzymatic activity of caspase-3 is shown in the presence
of D3.4, D3.4_S76R, D3.8, and E3_5 (control DARPin). Each DARPin was
added at three different concentrations: 10- (black), 100- (light gray), and
1,000-fold molar excess (gray). All DARPins inhibit the activity of caspase-3
with the exception of E3_5. Shown are the relative enzymatic activities of
caspase-6 (B) and 7 (C) in presence of four DARPins as described above.
The 1000-fold molar excess of DARPin was not measured for caspase-6
because no inhibition was observed at 100-fold molar excess. D3.8
shows a moderate inhibition of caspase-7; all other DARPins are specific for
caspase-3. Error bars represent the standard deviation of three independent
experiments.
See also Figures S3 and S4.
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Caspase-3 Directed DARPinsconnects the N-terminal capping repeat and the first internal
repeat of D3.4, and its side chain occupies the S4 pocket of
caspase-3 (Figure 5A). It forms a direct hydrogen bond with
Asn208-ND2 and two water-mediated hydrogen bonds with
Trp214-NE1 and Phe250-N (Figures 5A and S5). The main chain
carbonyl oxygen of Asp45 forms another water-mediated
(Wat10) hydrogen bond with Arg207-N of caspase-3. In other
caspase-3 structures Arg207-N participates in an antiparallel
b sheet with the substrate main chain. A water molecule (water
10) forms a third hydrogen bond with the hydroxyl group of-
Tyr204. As a consequence, Thr166 moves toward the active
site pocket and forms hydrogen bonds with Trp79-NE1 and
Lys111-NZ from D3.4 (Figures 5A and 6A).
The tip of loop-4 of caspase-3 is recognized by the concave
surface of D3.4 (Figures 5B and 5C). The side chain of Asp44
of D3.4 is buried in the interface and forms two hydrogen bonds
with Ser251-OG and Phe252-N. In contrast, the side chains of
Lys56 and Arg81 of D3.4 are solvent exposed and form salt
bridges with the Asp253 side chain of caspase-3. Hydrophobic
interactions seem to play equally important roles. The side chain
of Phe256 of caspase-3 fits into a pocket that is formed by Ala46,
Val48, Ile78, and Trp79 of D3.4. The benzyl ring of Phe256 of cas-
pase-3 forms T-stacking interactions with the indole ring of D3.4280 Structure 21, 277–289, February 5, 2013 ª2013 Elsevier Ltd All rights reserved
Table 2. X-Ray Data Collection and Model Refinement Statistics
Caspase-3/
D3.4 (2XZD)
Caspase-3/
D3.4_S76R (2Y0B)
Data Collection
Frame width () 0.25 0.2
Space group P3121 P3121
Unit cell parameter a = 98 A˚ a = 98 A˚
b = 98.0 A˚ b = 98.0 A˚
c = 193.6 A˚ c = 192.9 A˚
a = b = 90.0
g = 120.0
a = b = 90.0
g = 120.0
Resolution (A˚) 49.0–2.1 49.0–2.1
Wavelength (A˚) 1.000 0.92
Rsym (%) 4.2 (60.4) 4.9 (60.9)
Completeness (%) 99.3 (99.5) 99.2 (99.5)
I/s(I) 15.59 (1.92) 12.94 (1.96)
Refinement
Resolution (A˚) 2.1 2.1
RF/Rfree (%) 18.5/21.8 19.1/21.7
No. of protein atoms 5,616 5,622
No. of water atoms 247 345
Average B-factor (A˚2) 35.3 35.8
Root Mean Square Deviations
Bond length (A˚) 0.011 0.006
Bond angles () 1.192 0.941
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Caspase-3 Directed DARPinsTrp79 (Figure 5C). Although the Phe256 binding pocket is mainly
hydrophobic, the side chain of Asp77 is located at the bottom of
this pocket and forms an intramolecular salt bridge with Arg81
and a hydrogen bond with Wat26 (Figure 5C).
Comparison of the Caspase-3/D3.4 Structure
with Caspase-3 in Complex with XIAP and DEVD
The overall structure of caspase-3 is identical to several other
caspase structures. Superposition of the caspase-3/D3.4 struc-
ture with the caspase-3/z-DEVD-cmk (2DKO; Ganesan et al.,
2006) and the caspase-3/XIAP complex structures (1I3O; Riedl
et al., 2001) reveals rmsd values of 0.39 A˚ and 0.35 A˚, respec-
tively. Differences between caspase-3/D3.4 and the caspase-
3/z-DEVD-cmk structures are observed in the active site pocket.
In the caspase-3/D3.4 structure loop-4 of caspase-3 has moved
approximately 1 A˚ out of the active site, whereas Thr166 has
moved into the active site compared to the caspase-3/
z-DEVD-cmk structure (Figure 6A). The movement of Thr166 is
a consequence of the 120 rotation of the Tyr204 side chain. In
the caspase-3/z-DEVD-cmk structure Tyr204 points toward
Thr166, whereas in the caspase-3/D3.4 complex the Tyr204
side chain occupies the S2 pocket (Figure 6A).
The conformations of Tyr204 and loop-4 in the caspase-3/
D3.4 complex structure resemble the conformations seen in
the caspase-3/XIAP structure (1I3O) (Figure 6B). In both
complexes, Tyr204 occupies the S2 pocket (Riedl et al., 2001).
Furthermore, Tyr204 rests against a hydrophobic patch of the
inhibitor, which is formed by Leu141 and Val146 in XIAP and
by Ala46 and Ile78 in D3.4 (Figure 6B).Structure 21, 27Modeling the Caspase-3/D3.8 Complex Structure
Based on the sequence alignment and the competitive inhibition
we assume that D3.4 and D3.8 bind to the same epitope
with similar interactions. We were not able to crystallize the
caspase-3/D3.8 complex and thus calculated a homologymodel
of D3.8 based on a N3C DARPin E3_5 structure (1MJ0; Kohl
et al., 2003). This homology model was superimposed on D3.4
in the caspase-3/D3.4 crystal structure (Figure 6C). The N2C
DARPin D3.4 lacks the first internal repeat so that the N-cap
of D3.4 superimposes on the first internal repeat of the N3C
DARPin D3.8 (Figure 6C). Furthermore, D3.8 has two critical
mutations compared to D3.4. Mutations Lys56Ser and Ser76Arg
are located in the caspase/DARPin interface, whereas all
other amino acid changes between D3.4 and D3.8 are located
more than 4 A˚ away from caspase-3. The homology model
showed that the salt bridge between Lys56 and Asp253 is
absent in the D3.8/caspase-3 complex (Figure 6D). In D3.8 the
corresponding Ser56 is unable to form a salt bridge as observed
in the caspase-3/D3.4 structure. Furthermore, the positive
charge of Lys56 in D3.4 could cause repulsive interactions with
His255 at the top of loop-4 of caspase-7 (Figure 6D). These
repulsive interactions could explain why D3.4 does not show
any affinity for caspase-7, whereas D3.8 possesses weak affinity
for caspase-7 due to the Lys56Ser mutation.
D3.4 Mutant Ser76Arg
D3.8 binds caspase-3 with higher affinity and has a lower inhibi-
tion constant (Ki = 6.7 nM) compared to D3.4 (Table 1). Residue
Ser76 in D3.4 is located in proximity to the interface but does not
interact with caspase-3. The caspase-3/D3.8 model suggests
that a bulkier side chain, such as arginine, could participate in
an extended DARPin/caspase-3 interface. To test this hypoth-
esis we generated the D3.4 Ser76Arg mutant (D3.4_S76R)
and characterized its functional and structural properties.
D3.4_S76R revealed dissociation and inhibitory constants of
KD
S76R = 6.0 ± 0.5 nM and Ki
S76R = 3.49 ± 0.03 nM, respectively.
Thus, D3.4_S76R shows an equally low inhibitory constant for
caspase-3 compared to D3.8 (Table 1).
The 2.1 A˚ resolution crystal structure of the caspase-3/
D3.4_S76R complex revealed that although the overall structure
is identical to the caspase-3/D3.4 structure (rmsd of 0.198 A˚), the
C-terminal capping repeat has shifted by approximately 2 A˚ (Fig-
ure 6E). The side chain of the newly introduced Arg76 forms two
intramolecular hydrogen bonds with Gly80-O and Gln109-O of
the C-terminal capping repeat and an intermolecular hydrogen
bond with Gly60-O of caspase-3 (Figure 6E). In addition, the
weak hydrogen bond between Lys111 and Thr166 as it is seen
in the parent structure is broken and the Lys111 side chain points
into the active site forming a water-mediated hydrogen bond
with Gly165-O of caspase-3 and an intramolecular hydrogen
bond with Ile78-O from the preceding DARPin repeat. The medi-
ating water molecule is located in direct vicinity of the active site
Cys163 (Figure 6E).
DISCUSSION
The development of specific caspase inhibitors has remained
a challenging task due to the similarity between the active sites
of caspases. Although the selectivity of caspases for short7–289, February 5, 2013 ª2013 Elsevier Ltd All rights reserved 281
Figure 4. Structures of Caspase-3 in
Complex with Different Inhibitors
(A) Stereo view of the caspase-3/D3.4 complex
structure as a ribbon cartoon. The two chains of
caspase-3 are colored in dark (p17) and light gray
(p12). The active site L1, L2, and L4 loops and the
catalytic residues are highlighted in red and green,
respectively. D3.4 consists of N- and C-terminal
capping repeats (dark blue) and two internal
repeats (light blue). D3.4 binds in the active site
and interacts mainly with loop-4 of caspase-3.
(B) The superposition of the caspase-2 specific
DARPin AR_F8 (green, 2P2C) on the caspase-3/
D3.4 structure is shown in two different views.
Caspases are shown as a gray surface. Darpins
D3.4 (blue) and AR_F8 (green) recognize the active
site loop-4 (red), albeit from different sides.
(C) The caspase-3/XIAP structure (yellow, 1I3O)
was superimposed on the caspase-3/D3.4 struc-
ture. The C-terminal BIR2 domain of XIAP binds
outside the active side cleft and inhibits the
enzyme with the N-terminal tail.
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Figure 5. Binding Interface of Caspase-3 with D3.4
Close-up views of the caspase-3/D3.4 interaction in stereo. D3.4 (blue) interacts with caspase-3 (p17, dark gray; p12, light gray) via hydrogen bonds (dotted lines)
and hydrophobic interactions. Amino acids from the DARPin are labeled by an additional ‘. The active site cysteine is shown in green.
(A) Active site standard view: Asp45’ forms several hydrogen bonds in the S4 pocket of caspase-3. Thr166, which is located close to the active site Cys163, forms
two hydrogen bonds with the second repeat of D3.4.
(B and C) View from the backside of loop-4: The concave site of D3.4 recognizes the tip of loop-4 by several hydrogen bonds (B). The hydrophobic interactions in
the interface between caspase-3 and D3.4. Phe256 from caspase-3 binds into a hydrophobic pocket of D3.4 and forms T-stacking interactions with Trp79’ (C).
See also Figure S5.
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Caspase-3 Directed DARPinspeptide inhibitors that differ in the P4 positions is well estab-
lished (Thornberry et al., 1997), their selectivity is often insuffi-
cient considering the different amounts of active caspases in
cells undergoing apoptosis (Berger et al., 2006). In 2007, Schwe-
izer et al. published the first truly specific caspase inhibitor
(AR_F8) that inhibits caspase-2 with an allosteric mechanism
by interacting with loop-4 (Schweizer et al., 2007).Structure 21, 27Using the same technology (Binz et al., 2003), we identified
four caspase-3 DARPins, two of which specifically inhibited the
enzyme. Kinetic analysis characterized D3.4 and D3.8 as purely
competitive inhibitors, which is in agreement with the structural
data. In the caspase-3/D3.4 structure, the DARPin occupies
the active site pocket and recognizes loop-4 of caspase-3. The
caspase-2-directed DARPin AR_F8 also recognizes loop-4,7–289, February 5, 2013 ª2013 Elsevier Ltd All rights reserved 283
Figure 6. Structural Comparison of Caspase-3 Inhibitors
With the exception of caspase-3, the labels of all amino acids contain unique identifiers: D3.4 (’), DEVD (), XIAP (*), D3.4_S76R (^), D3.8 (D), and caspase-7 (#).
(A) Superposition of caspase-3/z-DEVD-fmk (light green andgray, 2DKO) on the caspase-3/D3.4 structure (dark gray andblue). Tyr204 is rotated by approximately
120 in the DARPin bound structure. As a consequence of this rotation Thr166 is shifted away from the active site. Movements are indicated by black arrows.
(B) Superposition of caspase-3/XIAP (gray and yellow, 1I3O) on the caspase-3/D3.4 structure (dark gray and blue) indicating a similar orientation of Tyr204 in
a subsite S2-blocking position.
(C) The D3.8 model (dark red and salmon represent the capping and internal repeats, respectively) superimposed on D3.4 (dark and light blue) with numbered
a helices in repeat 2 (D3.8) and 1 (D3.4), respectively. Caspase-3 is shown as a gray surface with loop-4 highlighted in red.
(D) Close-up view of the modeled interaction between either D3.4 (blue) or D3.8 (salmon) and either caspase-3 (gray) or caspase-7 (green). Shown are the
a helices 1 of the first internal repeat of D3.4 and the second internal repeat of the D3.8 model. In the caspase-3/D3.4 complex Lys56’ forms a salt bridge with
Asp253. In caspase-7, this position is occupied by His255#. In D3.8 Ser56D cannot form the salt bridge with caspase-3 and does not exert repulsive interactions
with His255# in caspase-7.
(E) Superposition of the caspase-3/D3.4 on the caspase-3/D3.4_S76R structure. Caspase-3 is shown as a gray surface with loop-4 colored in red, whereas D3.4
and D3.4_S76R are shown as dark blue and green Ca-traces. Interacting side chains are highlighted. Hydrogen bonds are indicated as gray dotted lines. In the
caspase-3/D3.4_S76R structure the side chain of Arg76^, Ile78^, and Lys111^ form hydrogen bonds that are not seen in the parent structure (Table 3) and cause
a shift of the C-cap.
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Table 3. Hydrogen Bonds in the Caspase-3/D3.4 Interface
DARPin Distance Caspase-3
D:ARG 23 [NH1] 3.19 C:PHE 252 [O]a
D:ASP 44 [OD2] 2.69 C:SER 251 [OG]a
D:ASP 44 [OD2] 2.97 C:PHE 252 [N]a
D:ASP 45 [OD1] 3.1 C:ASN 208 [ND2]b
D:ASP 45 [O] 2.5/2.8 C:Wat 10 - TYR 204 [OH]b
D:ASP 45 [OD2] 2.6/2.7 C:Wat 12 - PHE 250 [N]a
D:ASP 45 [OD2] 2.6/2.9 C:Wat 11 - TRP 214 [NE1]b
D:LYS 56 [NZ] 3.38 C:ASP 253 [OD1]a
D:LYS 56 [NZ] – C:ASP 253 [OD2]a
D:TRP 79 [NE1] 2.87 C:THR 166 [O]a
D:ARG 81 [NH2] 2.79 C:ASP 253 [OD2]a
D:LYS 111 [NZ] 3.75 C:GLU 167 [OE2]a
D:LYS 111 [NZ]c 2.68 C:THR 166 [OG1]a
D3.4_S76R
D:ARG 76 [NE] 3.3 C:GLY 60 [O]a
D:LYS 111 [NZ] 2.7/3.2 C:Wat - GLY 165 [O]a
aCaspase residues, not involved in subsite formation.
bCaspase residues, forming substrate binding pockets S4–S1.
cNot present in D3.4_S76R.
Figure 7. Schematic Caspase-3 Inhibition
(A) The peptide inhibitor Ac-DEVD-fmk occupies four substrate binding
pockets of caspase-3 (S1–S4).
(B) The BIR2 domain of XIAP occupies the S4 pocket of caspase-3 with
Asp146 and Val146 keeps Tyr204 at a position, which blocks the S2 pocket. S1
is filled with water molecules. Compared to Ac-DEVD-fmk the XIAPmain chain
runs in the opposite direction.
(C) D3.4 uses a caspase-3 inhibition mechanism that shares features of XIAP
and Ac-DEVD-fmk. The S4 pocket is also occupied (Asp45), Ile78 keeps
Tyr204 in a locked conformation and the S1 pocket is filled with water, but the
D3.4 main chain runs in the same direction like in Ac-DEVD-fmk.
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DARPin D3.4. Its kinetic characterization using the specific
velocity plot demonstrated a mixed type inhibition with a signifi-
cant part of uncompetitive inhibition. The different inhibition
modes of D3.4 and AR_F8 can be explained by the different
epitopes on the caspases. AR_F8 recognizes caspase-2 from
the backside of loop-4 and stabilizes a distinct conformation,
which is not able to bind the substrate, whereas D3.4 binds
straight into the active site of caspase-3. Our analysis further
showed that D3.4 prevents substrates from accessing the cata-
lytic Cys163 and leaves the conformation of loop-4 almost undis-
turbed when compared to the caspase-3 inhibitor structure.
Another finding is the superior inhibition of caspase-3 by the
closely related D3.8, which inhibits caspase-3 even better than
D3.4. DARPin molecules D3.6 and D3.13 bind caspase-3 but
do not inhibit hydrolysis and were thus not further analyzed.
D3.4 does not inhibit the closely related caspase-7 but from
the data given in Figure 2 the IC50 value for the inhibition of cas-
pase-7 by D3.8 can be estimated to be in the lower micro-molar
range. This residual activity is probably resulting from the
replacement of Lys56 in D3.4 to Ser56 in D3.8. Lys56 in D3.4
forms a salt bridge with Asp253 from caspase-3 and at the
same time could enforce a repulsive effect to His255 from cas-
pase-7 to ensure specificity for caspase-3. The model of the
less specific D3.8 does not show this repulsion at caspase-7,
which could explain the slight binding ability of D3.8 for
caspase-7. Thus, even inhibitors with significantly extended
interaction surfaces compared to tetrapeptide inhibitors can
recognize closely related caspases, albeit with affinity constants
that differ by at least three orders of magnitude.
Our inhibition studies using PARP-1 as a caspase substrate
revealed that the selected DARPins (D3.4, D3.4_S76R and
D3.8) inhibit PARP-1-cleavage by caspase-3 completely using
a 50-fold molar excess. In contrast, caspase-7 cleavage is notStructure 21, 27influenced even with a 100-fold excess of D3.4, D3.4_S76R, or
D3.8, respectively.
Our data suggest that D3.4 and D3.8 bind to the same
caspase-3 epitope because residues that seem to be crucial
for the recognition of this epitope, such as Asp45, Ala46,
Val48, Ile78, Trp79, and Arg81, are conserved in both molecules.
The crystal structure revealed that D3.4 recognizes caspase-3
by a set of specific hydrogen bonds, salt bridges and hydro-
phobic contacts (Table 3). Particularly interesting are the interac-
tions formed by Asp45, which occupies the S4 pocket. So far all
structurally characterized caspase-3 specific peptide inhibitors
harbor an aspartic acid that occupies this pocket (Figure 7).
Although the hydrogen bonding networks are different in the
structures of caspase-3 in complex with D3.4, z-DEVD-cmk or
XIAP, the positive electrostatic potential explains the preference
for a small and negatively charged hydrogen bonding partner like
aspartate. Further similarities between the complex structures of
caspase-3 with D3.4 and XIAP are seen for Tyr204 (Figure 7). In
both structures the Tyr204 side chain points toward Arg341,
placing the phenyl ring at van der Waals distance to Cys163-
Sg. On the opposite side the Tyr204 phenyl ring rests against
a hydrophobic core, which is composed of caspase-3 residues
Leu168 and Phe256 and the side chains of Ala46 and Ile78
from D3.4 or Leu141 and Val146 from XIAP. D3.4 and XIAP are7–289, February 5, 2013 ª2013 Elsevier Ltd All rights reserved 285
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caspase-3, which consequently is filled by water molecules. The
same conformation of Tyr204 is also seen in several other
structures of caspase-3 in complex with low molecular weight
inhibitors that are lacking a P1 aspartate (Agniswamy et al.,
2009; Ganesan et al., 2011) as well as in unliganded caspase-3
(Ni et al., 2003). Conversely, this conformation is different
from structures with classical tetrapeptide inhibitors, where the
Tyr204 side chain rests against the side chain of Thr166 (Gane-
san et al., 2006).
The main chains of the small peptide inhibitor z-DEVD.cmk
and D3.4 run antiparallel to caspase-3 residues 204–208. The
S4 pocket of caspase-3 is occupied by Asp1 and Asp45 of
z-DEVD.cmk and D3.4, respectively. In contrast to that the
main chain of XIAP runs parallel to caspase-3 with Val146 and
Asp148 binding into the S2- and the S4 pocket, respectively.
Although the main chains of D3.4 and XIAP run in opposite
directions, both inhibitors use very similar interactions to inhibit
caspase-3 (Figure 7). Thus, the comparison of the caspase-3/
D3.4 crystal structure with the caspase-3/XIAP crystal structure
provides an interesting example for the molecular mimicry of
natural and designed caspase-3 inhibitors.
In summary, our study presents the selection and character-
ization of caspase-3-directed DARPin inhibitors with implica-
tions for specificity and inhibition mechanism. The selected
DARPins D3.4 and D3.8 are pure competitive inhibitors. D3.4
and the improved variant D3.4_S76R are the first truly specific
caspase-3 inhibitors and do not bind caspase-7, a close
caspase-3 paralog, or any other human caspase. Such highly
specific binders/inhibitors are a prerequisite for the analysis
of the function of any enzyme involved in signaling pathways.
In the particular case of caspase-3 and its role in apoptotic
signaling, D3.4_S76R is the best molecule for such an analysis.
Remarkably D3.4 inhibits caspase-3 with a similar mechanism
compared to XIAP, the natural caspase-3 inhibitor that also
inhibits caspase-7. It has previously been postulated that spec-
ificity is achieved by two key factors, allosteric regulation and
scanning of large volumes of conformational space (Salvesen
andRiedl, 2007).While the second aspect holds true, we demon-
strate here that specificity can be achieved even when the
conserved substrate binding pockets are targeted, provided
this is combined with specific surface recognition of non-subsite
residues, which are unique to the targeted protein.EXPERIMENTAL PROCEDURES
DARPin Selection with Ribosome Display
We performed four rounds of ribosome display to enrich caspase-3 specific
binders based on a NI3C and NI2C library as described before (Binz et al.,
2004; Zahnd et al., 2007). Prior to each selection the DARPin-ribosome-
mRNA complex was incubated with the closest homologous of caspase-3
(caspase-6 and -7) and streptavidin for 30 min at 4C to avoid selection of
unspecific DARPins. Biotinylated caspase-3 was immobilized on magnetic
particles (Dynabeads, Invitrogen) for solution panning. DARPin selection was
performed in the absence of a caspase-3 inhibitor. The DARPin-ribosome-
mRNA complex was incubated with 20 ml of beads for 30 min at 4C in
a tube that was previously blocked with TBST-BSA (50 mM Tris-HCl pH 7.4,
150 mM sodium chloride, 0.05% Tween-20, 0.1% BSA). The incubation was
followed by four washing cycles in 50mMTris-acetate pH 7.4, 150mMsodium
chloride, 50 mM magnesium acetate, and 0.05% Tween-20. The RNA was
eluted in 50 mM Tris-acetate pH 7.4, 150 mM sodium chloride, and 25 mM286 Structure 21, 277–289, February 5, 2013 ª2013 Elsevier Ltd All rEDTA and transcribed into DNA for amplification. In rounds three and four,
we added a 1000-fold excess of unbiotinylated caspase-3 for 10 min during
the selection to favor the enrichment of DARPins with slow koff rates. After
four rounds of selection, we cloned the DARPin library in a pQE30 vector (-
QIAGEN), transformed competent XL1 blue cells (Stratagene), and continued
with crude cell extract ELISA.
Crude Cell Extract ELISA
Single colonies each containing one DARPin clone of the selected library were
picked and inoculated in 0.9 ml auto-inducing media 5052 (Studier, 2005) con-
taining deep 96-well plates (Abgene, UK). The cells were grown over night at
37C while shaking at 300 rpm in a shaker (TH15, Edmund Bu¨hler GmbH).
Then 200 ml of each well were transferred into a sterile 96-well plate
(449824, Nunc) as a backup for further protein expression and plasmid
preparation. The remaining 700 ml of cell-suspension was harvested by centri-
fugation and the cell pellet was lysed with 50 ml B-PER II (Pierce, 78260) per
well for 30 min shaking at room temperature. The lysed cells were resus-
pended by adding 950 ml PBS, pH 7.3, and cell debris were removed by centri-
fugation (20 min, 4500 rpm at 4C) in a tabletop centrifuge (Eppendorf). We
now took 20 ml of the supernatant of four 96 well plates and transferred it to
one 384-well ELISA plate (Nunc, 464718). This plate was previously coated
with 20 ml of a 22 nM neutravidin solution (Pierce, 31000) and biotinylated
caspase-3, followed by extensive washing. After 1 hr of incubation at room
temperature and three washing cycles, the plate was incubated with mouse
anti-RGS-H4 antibody (QIAGEN, 34650) at a dilution of 1:2000 in PBS 1%
BSA. After adding the secondary antibody (goat-a-mouse IgG alkaline phos-
phatase conjugate, Sigma, A3562) and four washing steps the amount of
bound DARPin was quantified by adding the substrate buffer (3 mM di-sodium
4-nitrophenyl phosphate, 50 mM sodium bicarbonate, 50 mM magnesium
chloride). The optical density (OD) was measured at 405 nm using a multiwell
plate reader (Infinite M1000, Tecan).
Expression, Purification, and Biotinylation of Proteins
All DARPins were expressed in auto-inducing media (Studier, 2005) or
lysogeny broth media (Binz et al., 2003). The expressed DARPin was purified
by IMAC using a self-made gravity column (Supelco, 57024) containing
0.5 ml bead volume of Ni2+-NTA agarose (QIAGEN, 30210). The DARPins
were eluted in PBS complemented with 200 mM imidazole. The imidazole
was removed with a PD-10 desalting column (GE Helthcare, 17-0435-01).
We added sodium azide to a final concentration of 0.03% to prevent growth
of bacteria and fungi. The DARPin solutions were stored at 4C. Caspase-1
to caspase-9 were expressed and purified as described elsewhere
(Roschitzki-Voser et al., 2012). Expression plasmids for caspase-6, -7, and -9
have been obtained from Dr. Guy Salvesen, the Burnham Institute, La Jolla,
CA, USA (Denault and Salvesen, 2003).
For chemical biotinylation of caspases, we used the linker EZ-Link Sulfo-
NHS-LC-LC-Biotin (Pierce, 21338), containing a reactive group, a 3.05-nm
long linker, and a biotin moiety. After purification, 1 ml of 10 mM caspase in
PBS, pH 7.3 was incubated with a 7-fold molar excess (1 ml of a 70 mM solu-
tion) of biotin on ice for 30 min. The reaction was quenched by adding 10 ml of
5 M Tris-HCl, pH 7.5. The biotinylated protein was purified by size exclusion
chromatography, using a Superdex 200 10/300 GL (GE Healthcare) in PBS
at 4C. Fractions containing biotinylated caspase were pooled and frozen in
liquid nitrogen after adding sucrose to a final concentration of 10%.
Crystallization
The caspase/DARPin complexes were formed by incubating caspase-3 with
a 2-fold molar excess of each DARPin for 10min on ice. The complex was puri-
fied by size exclusion chromatography (Superdex 200 HR 10/30, Amersham
Pharmacia, Sweden) in 50 mM Tris-HCl, pH 8.0 (4C), 50 mM sodium chloride.
Fractions containing caspase/DARPin were concentrated to 5 mg/ml and
10 mg/ml for D3.4 and D3.4_S76R, respectively, using an ultrafiltration device
with a molecular weight limit of 15 kDa (Amicon Ultra, Millipore).
Crystals were grown at room temperature using the vapor-diffusion method.
Two microliters of concentrated protein solution were mixed with 1 ml of reser-
voir solution containing 100 mM HEPES, pH 7.3, 70% (v/v) 2-methyl-2,4-
pentanediol. Crystallization plates were stored at 20C. Crystals appeared
within 24 hr.ights reserved
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For X-ray diffraction analysis, crystals were flash-frozen in liquid nitrogen and
data were collected (100 K) at beamline X06SA (Swiss Light Source, Villigen,
Switzerland). No cryoprotectant was necessary for data collection. The
beamline was equipped with a Pilatus 6M fast readout pixel detector (Dectris,
Switzerland). The program XDS was used for data processing and data were
scaled with XSCALE (Kabsch, 2010; Potterton et al., 2003). Both complexes
crystallized in space group P3121. Unit cell dimensions are listed in Table 2.
The structures were solved by molecular replacement with the program
PHASER (McCoy et al., 2007) using a high-resolution structure of caspase-3
(2DKO; Ganesan et al., 2006) and a model of the N2C DARPin, which was
generated by homology modeling (MODELER 9v8; Eswar et al., 2007) using
the N3C DARPin E3_5 (1MJ0; Kohl et al., 2003) as a template. The crystals
have a solvent content of 59% (Matthews coefficient of 3.0 A˚3/Da) (Collabora-
tive Computational Project, Number 4, 1994) with one (p12, p17, D3.4)2
complex in the asymmetric unit. Alternating rounds of manual model building
using COOT (Emsley et al., 2010) and restrained refinement using REFMAC
version 5.5.01.09 (Murshudov et al., 1997) yielded RF/Rfree values of 0.185/
0.217 for the caspase-3/D3.4 and 0.174/0.214 for the caspase-3/D3.4_S76R
complex. Data collection and structure refinement statistics are listed in
Table 2. Structures were superimposed using COOT (Emsley et al., 2010)
and figures were prepared using PyMOL (Schrodinger, 2010).
Site-Directed Mutagenesis
We used the QuikChange Site Directed Mutageneis Kit (Stratagene) to incor-
porate mutations in the DARPin sequence. The following primers were used
to introduce the Ser76Arg mutation in D3.4: 50-GGT GCT GAC GTT AAC
GCT CGT GAC ATT TGG GGT CGT ACT-30 (fwd) and 50-AGT ACG ACC
CCA AAT GTC ACG AGC GTT AAC GTC AGC ACC-30 (rev). The underlined
codons indicate the mutation.
Surface Plasmon Resonance Analysis
For SPR experiments we used the Proteon XPR36TM (Biorad Laboratories)
and a NLC sensor chip (Biorad Laboratories). Sterile filtered PBS, pH 7.3,
and 0.005% Tween-20 were used as the standard buffer for all coating and
kinetic analysis steps. A 5-nM solution of biotinylated, fully processed caspase
was coated in the absence of caspase inhibitors on the sensor chip at a
flow rate of 30 ml per minute. The coating procedure was stopped when
1000 relative units were immobilized on the chip. Dilution series of DARPins
were pipetted in 96-deep well plates (Biorad, 176-6023), which were sealed
to prevent evaporation and contamination with dust particles. Starting with
the lowest concentration we measured the binding of DARPins at 0, 0.176,
0.52, 1.58, 4.47, 14.2, 42.6, and 128 nM concentrations. All experiments
were performed at 20C. Flow rates of 100 ml per minute, association times
of 3 min and dissociation times of 20 min were used. Data were recorded
and kinetic binding data were determined with the ProteOn Manager 2.1.1
software (Biorad) using the heterogeneous ligand model (Bravman et al.,
2006).
Caspase Activity Measurements
Specific inhibition of caspase-1 to caspase-9 was measured using peptide
substrates from Peptide Institute (Osaka, Japan). We used Ac-DEVD-amc
for caspase-3, -6, -7, and -8; Ac-WEHD-amc for caspase-1, -4, and -5;
Ac-VDVAD-amc for caspase-2; and Ac-LEHD-amc for caspase-9. Enzyme
and substrate concentrations in the assay were as follows: caspase-1
(10 nM enzyme; 150 mM substrate), caspase-2 (25 nM; 150 mM), caspase-3
(0.5 nM; 150 mM), caspase-4 (200 nM; 600 mM), caspase-5 (10 nM; 150 mM),
caspase-6 (10 nM; 600 mM), caspase-7 (2 nM, 400 mM), caspase-8 (10 nM;
150 mM), and caspase-9 (25 nM, 600 mM) considering all caspases as hetero-
tetramers. DARPins were added assuming that one DARPin binds to every
caspase active site. The following assay buffers were used: caspase-2,
100 mM MES, pH 6.5, 10% PEG600 (w/v), 0.1% CHAPS (w/v), 10 mM DTT;
caspase-9, 50 mM Tris-HCl, pH 7.5, 10% sucrose (w/v), 1.3 M sodium
citrate; all other caspases, 20 mM PIPES, pH 6.5, 10% sucrose (w/v), 0.1%
CHAPS (w/v), 10 mM DTT, 150 mM sodium chloride, and 1 mM EDTA. AMC
release was monitored by measuring the fluorescent excitation and emission
wavelengths of 360 nm and 465 nm, respectively, using an Infinite M-1000
spectrofluorometer (Tecan).Structure 21, 27Specific Velocity Plot
Inhibition mechanism and Ki values of DARPins D3.4, D3.8, and D3.4_S76R
have been determined using the specific velocity plot (Baici, 1981). The
concentration of caspase-3 was determined by active site titration as
described previously (Stennicke et al., 2000). The caspases inhibitor Ac-
DEVD-cmk (0 to 7.6 nM), caspase-3 (0.5 nM), and the substrate Ac-DEVD-
amc (100 mM) were prepared in activity buffer containing no DTT (20 mM
PIPES, pH 6.5, 10% sucrose [w/v], 0.1% CHAPS [w/v], 150 mM sodium chlo-
ride, 1 mM EDTA). Concentrations of DARPins were determined using amino
acid analysis at the Functional Genomic Center (Zu¨rich, Switzerland). The
initial velocities of substrate hydrolysis with 0.5 nM caspase-3 have been
measured at different DARPin concentrations (D3.4, 8–32 nM; D3.4_S76R,
4–10 nM; D3.8, 2–8 nM) and substrate concentration between 0.2 and 0.8
times Km (Km = 24.7 ± 1.8 mM). Graphical analysis of the velocity plot was
done with Prism5 (GraphPad Software). The inhibitor titration has been per-
formed using 0.5 nM caspase-3, different DARPin concentrations (D3.4,
0–1,000 nM; D3.4_S76R, 0–1,000 nM; D3.8, 0–100 nM), and 24 mM substrate.
To determine Ki values of DARPins initial velocities were fitted to the tight
binding inhibition equation as described previously (Szedlacsek et al., 1988).
PARP-1 Inhibition and Western Blot Analysis
A 0.18-mM solution of PARP-1 in 50 mM Tris-HCl, pH 7.5, 150 mM sodium
chloride was mixed with either 40 nM caspase-3 or 150 nM caspase-7 and
the corresponding DARPin (10- to 100-fold excess per active site) as indicated
in Figure 2. The mixture was incubated for 20 min at room temperature in
50 mM Tris-HCl pH 7.5, 150 mM sodium chloride, and 0.5 mM DTT, and
stopped by adding SDS sample buffer (95C for 5min). The samples were sub-
jected to 12% SDS-PAGE under reducing conditions and transferred to a
nitrocellulose membrane (iBlot, Invitrogen). The membrane was blocked in
high-TBS (50 mM Tris-HCl, pH 7.5, 500 mM sodium chloride) containing 5%
(w/v) nonfat dry milk for 1 hr at room temperature. The primary PARP antibody
(Cell Signaling, 9542) was incubated with the membrane at a dilution of 1:1000
in high-TBS-T (50 mM Tris-HCl, pH 7.5, 500 mM sodium chloride, 0.1%
Tween-20) at 4C overnight. After intensive washing in high-TBS-T, we incu-
bated themembrane with anti-rabbit HRP conjugated antibody (Cell Signaling,
7074) for 1 hr at room temperature in TBS (50 mM Tris-HCl, pH 7.5, 150 mM
sodium chloride). Protein bands were visualized by chemiluminescence using
the SuperSignal West Pico Chemiluminescent Substrate (Pierce) in combina-
tion with a Fuji Las 3000 camera.
Modeling of D3.8
Based on the kinetic data and sequence alignments, we hypothesized that
D3.8 binds to the same epitope as D3.4. Therefore, we generated a model
of D3.8 in complex with caspase-3. The N3C DARPin E3_5 (1MJ0; Kohl
et al., 2003) was used as a template to calculate a homology model of D3.8
using the program MODELER 9v8 (Eswar et al., 2007). The model of D3.8
was then superimposed on D3.4 in the complex structure according to the
sequence alignment shown in Figure 1.
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